Bellaterra (Barcelona), October 2026 – As it gets ready for its first study in patients, Tirecat Health has added clinical, product and regulatory expertise to its team. The new members joined the founders in 2026 and were presented to the company’s partners in October.
Who joins and what they do
Dr. Judit Ruiz Calbet, MD – Clinical Expert
A medical doctor, Judit leads Tirecat Health’s clinical strategy and the coordination of its clinical studies. She is the company’s link with hospitals and clinicians, advises on the choice of sites and investigators, and contributes to the design of the study protocol, endpoints and patient selection.
Dr. José D. Bolaños – Product Developer
A postdoctoral researcher in the NANOSFUN group at ICN2, José leads the scale-up of the synthesis and its transfer to manufacturing, the quality control of each batch and the validation of the antimicrobial activity of the membrane, including against resistant bacteria. He also generates the design and manufacturing data for the regulatory file.
Dr. Verónica Arévalo – Regulatory & Business Development
Verónica is a fellow of the “la Caixa” Foundation, whose Health Innovation Fellowships fund her incorporation into Tirecat Health. She works on the regulatory technical file of RESKIN together with the company’s regulatory partners, and on funding applications, partnerships and investor meetings.
A team built around the clinic
The new members work alongside the co-founders, Dr. Salvio Suárez-García (CTO) and Prof. Daniel Ruiz-Molina (CSO). Before designing its first clinical study, the team interviewed 35 clinicians in chronic wounds, infectious diseases and surgery in Spain and Italy, and built a network that includes 7 hospitals and 6 research groups.


In 2026 the technology behind RESKIN also received the Duran Farell Award for Technological Innovation (UPC – Fundación Naturgy), granted to the NANOSFUN group at ICN2-CSIC.
Follow our progress
News, milestones and calls for collaboration, first on LinkedIn.

